March 19, 2009: NanoVentures Australia has registered a new company, Quintain NanoSystems, to develop nanoparticle-based imaging and diagnostic tools.
Quintain has a portfolio of contrast agent technologies developed with the University of Melbourne, the Baker Heart Research Institute, and RMIT University. Led by Jeanette Pritchard, the Qunitain team has had discussions with potential development partners and investors, and will be presenting to potential stakeholders through April and May of 2009, according to a NanoVentures news release.
Quintain NanoSystems (Quintain NS) is the vehicle established in 2007 from the bionanotechnology activities of Nanotechnology Victoria Ltd. Its focus is toward development and commercialization of diagnostic reagents and devices for human and animal health industries.